AI-extracted from the 10-Q filed 2026-08-06 — Q3 FY2026 (quarter ended June 30, 2026). Every figure is machine-verified against the filing text on SEC EDGAR.
Continuing operations revenue of $4.983B (+5.4% YoY) driven by Medical Essentials, Connected Care, and Interventional segments, offset by $450M non-cash asset impairment charges.
Biggest Revenue Drivers
Interventional$1,414M+6.4% YoY
Strength in Peripheral Intervention oncology products, double-digit growth in Urology/Critical Care PureWick offerings and Surgery infection prevention products.
Medical Essentials$1,675M+4.5% YoY
Strong U.S. Medication Delivery Solutions infusion share gains and Specimen Management Vacutainer portfolio growth, partially offset by China VoBP impacts.
Biggest Revenue Drivers
Total revenue: $4,983M+5.4% YoY
Interventional$1,414M+6.4% YoY
Strength in Peripheral Intervention oncology products, double-digit growth in Urology/Critical Care PureWick offerings and Surgery infection prevention products.
Medical Essentials$1,675M+4.5% YoY
Strong U.S. Medication Delivery Solutions infusion share gains and Specimen Management Vacutainer portfolio growth, partially offset by China VoBP impacts.
Connected Care$1,224M+4.9% YoY
Strong Medication Management Solutions backlog and Advanced Patient Monitoring continued Acumen IQ adoption and consumables growth.
BioPharma Systems$670M+6.6% YoY
Double-digit prefillable solutions growth in biologic/GLP-1 delivery products, offset by lower vaccine demand.
Largest Expense Items
Cost of products sold$2,668M+7.1% YoY
Tariffs, higher labor costs, and El Paso Warning Letter remediation charges, partially offset by manufacturing efficiency improvements.
Selling and administrative expense$1,261M+8.4% YoY
Higher selling and shipping costs from inflationary pressures and investments in strategic growth regions.
Integration, restructuring and transaction expense$89M-7.3% YoY
Restructuring and integration costs; excludes $450M non-cash asset impairment charges recorded in Q2 for operational exit decisions.
Margins: Gross profit margin declined 90 basis points to 46.4% YoY, primarily due to tariffs, labor cost inflation, and El Paso facility remediation costs, partially offset by manufacturing efficiency gains from BD Excellence continuous improvement initiatives. Operating margin pressure reflected higher selling/administrative expenses and elevated restructuring charges.
Watch Items from the Filing
Hernia Product Claims: approximately 7,090 claims outstanding as of June 30, 2026 (vs. 6,905 at Sept 30, 2025); settlement agreement in place with payments over multi-year period. Implantable Ports: ~3,850 claims with first trial (April 2026) resulting in defense verdict on 2 claims, mistrial on 2 others; next trials scheduled August and October 2026.
FDA Warning Letters: El Paso facility (April 2026) cited deficiencies in current good manufacturing practice, laboratory controls, and equipment cleaning for ChloraPrep/PurPrep drug-device products; $450M non-cash impairment recorded Q2 2026. Dispensing Warning Letter (Nov 2024) to San Diego facility; commitments completed but further FDA action possible.
Tariff Impact: unfavorably impacted Q3 operating expense; company expects continued adverse impact for FY2026 and potentially beyond due to global supply chain exposure; mitigation strategies (sourcing optimization, exemptions) remain uncertain in timing and effectiveness.
China Market Dynamics: volume-based procurement programs and government cost-containment driving decline in Medical Essentials Medication Delivery Solutions and Interventional Peripheral Intervention revenues; emerging markets down 2.6% on FX-neutral basis.
Ethylene Oxide Sterilization Regulation: FDA revised NESHAP effective April 2024; company received Presidential exemption (July 2025) through July 2027 but continues implementing compliance measures requiring additional technology investments and ongoing operational costs.
AI-extracted and verified against SEC EDGAR filing text. Not investment advice.
Menziuso PeterEVP and President, BDIGrant or award · Jun 1, 2026
Neal Shana CarolEVP and Chief People OfficerShares withheld for tax or exercise price · Apr 6, 2026
Congress trading in BDX
22 transactions in BDX reported by 11 members of Congress under the STOCK Act, most recent trade May 21, 2026. Reported transactions, not recommendations.
About BECTON DICKINSON & CO (BDX): stock profile, AI score and financials
BECTON DICKINSON & CO (BDX) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. 13F Pro's AI-powered ranking engine scores BDX at 61.5/100 on a composite quality score built from its SEC filings, placing it at rank #774 of 2,925 stocks — the top half of the AI-ranked universe. BDX scores in the top quartile across earnings quality (94.9), revenue scale (93.3). Areas of concern include profitability (34.9), which score below median versus the broader universe. Based on the latest XBRL financial filings (Q3 2026), BECTON DICKINSON & CO reports quarterly revenue of $5.0B, net income of $377.0M, an operating margin of 13.3%. Top institutional holders of BDX by reported 13-F value include BlackRock, VANGUARD CAPITAL MANAGEMENT, MASSACHUSETTS FINANCIAL SERVICES, based on the most recent SEC filings. BDX trades on the NYSE exchange and files with the SEC under CIK 10795. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate BDX daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for BECTON DICKINSON & CO directly from SEC EDGAR.